Shares of Iovance Biotherapeutics, Inc. IOVA surged 32.7% in after-hours trading on February 16, following the FDA’s announcement of the accelerated approval of Amtagvi (lifileucel) suspension. The drug has been granted approval to treat advanced melanoma after anti-PD-1 and targeted therapy, marking a significant milestone for the company.
Iovance Breaks Ground in Cancer Treatment
Amtagvi’s approval signifies the first and only one-time T cell therapy given the green light by the FDA for the treatment of solid tumor cancer. This accomplishment is a historic step in cancer treatment, particularly for advanced melanoma patients who have exhausted standard-of-care medications. This regulatory nod solidifies Iovance’s position as a pioneering force in the oncology space.
Impending Clinical Trials and Future Prospects
Following this success, Iovance is poised to conduct the phase III TILVANCE-301 study, evaluating Amtagvi in frontline advanced melanoma. The results of this study are expected to pave the way for the drug’s traditional approval in this crucial indication. This development promises to unlock vast opportunities for Iovance and its shareholders in 2024 and beyond, underscoring the company’s potential to revolutionize cancer treatment.
Risks Amidst Opportunities
Despite the positive news, it’s crucial to note that Amtagvi’s approval comes with a boxed warning for potential treatment-related risks such as mortality, severe cytopenia, infection, and cardiopulmonary and renal impairment. While celebrating this milestone, investors must remain vigilant and take these risks into account as they evaluate Iovance’s future performance.
Image Source: Zacks Investment Research
Investment Outlook
Iovance currently holds a Zacks Rank #4 (Sell). Investors seeking alternate opportunities in the healthcare sector may consider exploring Exact Sciences Corp. and Puma Biotechnology, Inc., both of which currently carry a Zacks Rank #1 (Strong Buy). These companies exhibit strong potential and may present favorable alternatives for investment in the healthcare space.
While celebrating this milestone, investors must remain vigilant and take these risks into account as they evaluate Iovance’s future performance.
It’s only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it’s positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
